The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
The biopharmaceutical manufacturing sector stands at the brink of a revolution, driven by the relentless pursuit of speed, safety, and scalability. The emergence of new therapeutic modalities, coupled with the increasing demand for rapid and cost-effective production solutions, has necessitated a
Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and
The pharmaceutical packaging industry stands at the precipice of a significant transformation. With an anticipated growth from $110.55 billion in 2024 to $176.94 billion by 2032, driven by the increasing prevalence of biologics, stringent regulations, and the menace of drug counterfeiting, it is
The biotechnology industry is currently experiencing a wave of renewed interest, particularly in the field of immunology. A shining example of this trend is Upstream Bio, a Massachusetts-based firm that recently made headlines with its $255 million initial public offering (IPO). The substantial
The recent reaffirmation of Piper Sandler's Overweight rating for Sutro Biopharma (NASDAQ: STRO) has sparked investor interest. While the company's shares have experienced significant volatility, the solid clinical advancements and strategic partnerships suggest potential growth.
